At baseline (T1), and regardless of hormone receptor status, of all eligible patients screened (N = 176) 25.6% (n = 45) were found to be at major/medium depression risk; 33.5% (N = 59) showed minor depression symptoms; and 41% (N = 72) were not depressed. Here, NR4A1 is linked to depressive disorder.